Skip to main content

NBY

Stock
Health Care
Biotechnology

Performance overview

NBY Price
Price Chart

Forward-looking statistics

Beta
0.61
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.

Company info

SectorHealth Care
IndustryBiotechnology
Employees41
Market cap$3.1M

Fundamentals

Enterprise value-$4.0M
Revenue$9.8M
Revenue per employee
Profit margin37.43%
Debt to equity18.24

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$24.38
Dividend per share$1.00
Revenue per share$2.08
Avg trading volume (30 day)$18K
Avg trading volume (10 day)$13K
Put-call ratio

Macro factor sensitivity

Growth-12.2
Credit+6.2
Liquidity+6.1
Inflation-6.3
Commodities-4.2
Interest Rates-3.5

Valuation

Dividend yield158.73%
PEG Ratio-0.77
Price to sales0.37
P/E Ratio-0.77
Enterprise Value to Revenue-0.41
Price to book0.59

Upcoming events

Next earnings dayApril 3, 2025
Next dividend day
Ex. dividend dayJune 14, 2006

News

NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (December 25, 2024)
NovaBay Acquires Skincare-Focused Firm For $15M

NovaBay Pharmaceuticals Inc (NYSE: NBY) has agreed to acquire DERMAdoctor LLC, a privately-held company that commercializes dermatologist-developed skincare products, for $15.0 million. The deal value includes $12.0 million in cash and an additional $3 million in earnout payments contingent upon the DERMAdoctor business achieving predetermined financial targets for the 2022 and the 2023 fiscal years.

Benzinga (September 28, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free